Increased coupling of caveolin-1 and estrogen receptor α contributes to the fragile X syndrome

Annals of Neurology

Volumn 77, Issue 4, 2015, Pages 618-636

  Yang, Qi ^a   Yang, Le ^a   Zhang, Kun ^a   Guo, Yan Yan ^a   Liu, Shui Bing ^a   Wu, Yu Mei ^a   Li, Xiao Qiang ^a   Song, Qian ^b   Zhuo, Min ^b,c   Zhao, Ming Gao ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; SHORT HAIRPIN RNA; AMPA RECEPTOR; FMR1 PROTEIN, MOUSE; FRAGILE X MENTAL RETARDATION PROTEIN; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; PROTEIN BINDING;

ADULT; ANIMAL EXPERIMENT; ANTERIOR CINGULATE; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGICAL PROCEDURES; FEMALE; FRAGILE X SYNDROME; IMMUNOPRECIPITATION; LONG TERM POTENTIATION; MOUSE; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY;

ANIMALS; CAVEOLIN 1; ESTROGEN RECEPTOR ALPHA; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MICE; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; PROTEIN BINDING; RECEPTORS, AMPA;

EID: 84925678760     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24358     Document Type: Article

References (69)

1. Loesch DZ, Huggins RM, Hagerman RJ,. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10: 31-41.
2. Skinner M, Hooper S, Hatton DD, et al. Mapping nonverbal IQ in young boys with fragile X syndrome. Am J Med Genet A 2005; 132A: 25-32.
3. Turner G, Webb T, Wake S, Robinson H,. Prevalence of fragile X syndrome. Am J Med Genet 1996; 64: 196-197.
4. O'Donnell WT, Warren ST,. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 2002; 25: 315-338.
5. Feng Y, Zhang F, Lokey LK, et al. Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995; 268: 731-734.
6. Zhao MG, Toyoda H, Ko SW, et al. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci 2005; 25: 7385-7392.
7. Tranfaglia MR,. Fragile X syndrome: a psychiatric perspective. Results Probl Cell Differ 2012; 54: 281-295.
8. Hessl D, Glaser B, Dyer-Friedman J, et al. Cortisol and behavior in fragile X syndrome. Psychoneuroendocrinology 2002; 27: 855-872.
9. Bourgeois JA, Cogswell JB, Hessl D, et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 2007; 29: 349-356.
10. Mitchell ES, Woods NF,. Cognitive symptoms during the menopausal transition and early postmenopause. Climacteric 2011; 14: 252-261.
11. Henderson VW,. Menopause, cognitive ageing and dementia: practice implications. Menopause Int 2009; 15: 41-44.
12. Woods NF, Smith-Dijulio K, Percival DB, et al. Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women's Health Study. J Womens Health (Larchmt) 2007; 16: 667-677.
13. Boulware MI, Weick JP, Becklund BR, et al. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 2005; 25: 5066-5078.
14. Mermelstein PG, Becker JB, Surmeier DJ,. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci 1996; 16: 595-604.
15. Qiu J, Bosch MA, Tobias SC, et al. Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J Neurosci 2003; 23: 9529-9540.
16. Niswender CM, Conn PJ,. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010; 50: 295-322.
17. Gutkind JS,. Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE 2000; 2000:re1.
18. Neves SR, Ram PT, Iyengar R,. G protein pathways. Science 2002; 296: 1636-1639.
19. Stern CM, Mermelstein PG,. Caveolin regulation of neuronal intracellular signaling. Cell Mol Life Sci 2010; 67: 3785-3795.
20. Krajewska WM, Maslowska I,. Caveolins: structure and function in signal transduction. Cell Mol Biol Lett 2004; 9: 195-220.
21. Willemsen R, Oostra BA, Bassell GJ, Dictenberg J,. The fragile X syndrome: from molecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev 2004; 10: 60-67.
22. Schlegel A, Wang C, Katzenellenbogen BS, et al. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 1999; 274: 33551-33556.
23. Razandi M, Oh P, Pedram A, et al. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 2002; 16: 100-115.
24. Boulware MI, Kordasiewicz H, Mermelstein PG,. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci 2007; 27: 9941-9950.
25. Grove-Strawser D, Boulware MI, Mermelstein PG,. Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neuroscience 2010; 170: 1045-1055.
26. Yang Q, Yang ZF, Liu SB, et al. Neuroprotective effects of hydroxysafflor yellow A against excitotoxic neuronal death partially through down-regulation of NR2B-containing NMDA receptors. Neurochem Res 2010; 35: 1353-1360.
27. Liu SB, Zhang N, Guo YY, et al. G-protein-coupled receptor 30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-containing NMDA receptors. J Neurosci 2012; 32: 4887-4900.
28. Zhao MG, Toyoda H, Lee YS, et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 2005; 47: 859-872.
29. Oka H, Shimono K, Ogawa R, et al. A new planar multielectrode array for extracellular recording: application to hippocampal acute slice. J Neurosci Methods 1999; 93: 61-67.
30. Yang Q, Feng B, Zhang K, et al. Excessive astrocyte-derived neurotrophin-3 contributes to the abnormal neuronal dendritic development in a mouse model of fragile X syndrome. PLoS Genet 2012; 8: e1003172.
31. Kuzhikandathil EV, Clark L, Li Y,. The extracellular cAMP-adenosine pathway regulates expression of renal D1 dopamine receptors in diabetic rats. J Biol Chem 2011; 286: 32454-32463.
32. Li J, Geng S, Xie X, et al. Caveolin-1-mediated negative signaling plays a critical role in the induction of regulatory dendritic cells by DNA and protein coimmunization. J Immunol 2012; 189: 2852-2859.
33. Lee KJ, Kim H, Kim TS, et al. Morphological analysis of spine shapes of Purkinje cell dendrites in the rat cerebellum using high-voltage electron microscopy. Neurosci Lett 2004; 359: 21-24.
34. Harris KM, Jensen FE, Tsao B,. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci 1992; 12: 2685-2705.
35. Adams MM, Fink SE, Janssen WG, et al. Estrogen modulates synaptic N-methyl-D-aspartate receptor subunit distribution in the aged hippocampus. J Comp Neurol 2004; 474: 419-426.
36. Smith CC, McMahon LL,. Estradiol-induced increase in the magnitude of long-term potentiation is prevented by blocking NR2B-containing receptors. J Neurosci 2006; 26: 8517-8522.
37. Man HY, Sekine-Aizawa Y, Huganir RL,. Regulation of {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking through PKA phosphorylation of the Glu receptor 1 subunit. Proc Natl Acad Sci U S A 2007; 104: 3579-3584.
38. Snyder GL, Allen PB, Fienberg AA, et al. Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J Neurosci 2000; 20: 4480-4488.
39. Zadran S, Qin Q, Bi X, et al. 17-Beta-estradiol increases neuronal excitability through MAP kinase-induced calpain activation. Proc Natl Acad Sci U S A 2009; 106: 21936-21941.
40. Hu H, Qin Y, Bochorishvili G, et al. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci 2008; 28: 7847-7862.
41. Li J, Pelletier MR, Perez Velazquez JL, Carlen PL,. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002; 19: 138-151.
42. Wang H, Wu LJ, Kim SS, et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008; 59: 634-647.
43. Courtney SM, Petit L, Maisog JM, et al. An area specialized for spatial working memory in human frontal cortex. Science 1998; 279: 1347-1351.
44. Bear MF, Huber KM, Warren ST,. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27: 370-377.
45. Moon J, Beaudin AE, Verosky S, et al. Attentional dysfunction, impulsivity, and resistance to change in a mouse model of fragile X syndrome. Behav Neurosci 2006; 120: 1367-1379.
46. Zhao MG, Ko SW, Wu LJ, et al. Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci 2006; 26: 8923-8930.
47. Sandstrom NJ, Williams CL,. Memory retention is modulated by acute estradiol and progesterone replacement. Behav Neurosci 2001; 115: 384-393.
48. Frye CA, Rhodes ME,. Enhancing effects of estrogen on inhibitory avoidance performance may be in part independent of intracellular estrogen receptors in the hippocampus. Brain Res 2002; 956: 285-293.
49. Kooy RF,. Of mice and the fragile X syndrome. Trends Genet 2003; 19: 148-154.
50. Hayashi Y, Shi SH, Esteban JA, et al. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 2000; 287: 2262-2267.
51. Kessels HW, Malinow R,. Synaptic AMPA receptor plasticity and behavior. Neuron 2009; 61: 340-350.
52. Moriarty K, Kim KH, Bender JR,. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006; 147: 5557-5563.
53. Liu F, Day M, Muniz LC, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci 2008; 11: 334-343.
54. Rakhade SN, Fitzgerald EF, Klein PM, et al. Glutamate receptor 1 phosphorylation at serine 831 and 845 modulates seizure susceptibility and hippocampal hyperexcitability after early life seizures. J Neurosci 2012; 32: 17800-17812.
55. Lee HK, Takamiya K, He K, et al. Specific roles of AMPA receptor subunit GluR1 (GluA1) phosphorylation sites in regulating synaptic plasticity in the CA1 region of hippocampus. J Neurophysiol 2010; 103: 479-489.
56. Lee HK, Barbarosie M, Kameyama K, et al. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 2000; 405: 955-959.
57. Shepherd JD, Huganir RL,. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol 2007; 23: 613-643.
58. Dolen G, Bear MF,. Courting a cure for fragile X. Neuron 2005; 45: 642-644.
59. Chung HJ, Xia J, Scannevin RH, et al. Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. J Neurosci 2000; 20: 7258-7267.
60. Seidenman KJ, Steinberg JP, Huganir R, Malinow R,. Glutamate receptor subunit 2 serine 880 phosphorylation modulates synaptic transmission and mediates plasticity in CA1 pyramidal cells. J Neurosci 2003; 23: 9220-9228.
61. Huber KM, Gallagher SM, Warren ST, Bear MF,. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002; 99: 7746-7750.
62. Vasudevan N, Pfaff DW,. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocr Rev 2007; 28: 1-19.
63. Toran-Allerand CD, Guan X, MacLusky NJ, et al. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 2002; 22: 8391-8401.
64. Bagni C, Greenough WT,. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 2005; 6: 376-387.
65. Juhasz M, Vertesaljai M, Herszenyi L, et al. The role of caveolin-1 gene in carcinogenesis [in Hungarian]. Orv Hetil 2004; 145: 1985-1989.
66. Williams TM, Lisanti MP,. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288: C494-C506.
67. Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U,. Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet 2001; 103: 226-230.
68. Engelman JA, Chu C, Lin A, et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998; 428: 205-211.
69. Zhou Y, Watters JJ, Dorsa DM,. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 1996; 137: 2163-2166.